TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27030629
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (C)
Study: 25377429
Drug: Pregabalin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 2.5 mg/kg/day
Study: 25377429
Drug: Pregabalin 15
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 15 mg/kg/day
Study: 25377429
Drug: Pregabalin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (up to 10 mg/kg/day for ages 1 month to 16 years; up to 15 mg/kg/day for ages <6 years)
Study: 21512813
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg intravenously before tourniquet inflation and 3 hours postoperatively; 250 mg orally, two capsules three times daily for 5 days)
Study: 16060124
Drug: Torsemide (29
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torsemide (29 mg, range 0-160 mg) every 6 h
Study: 16060124
Drug: Furosemide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (60 mg, range 0-240 mg) every 6 h
Study: 2277569
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose epidural morphine (2 mg) and 75 mg diclofenac sodium i.m. postoperatively (Group B)
Study: 2277569
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose epidural morphine (2 mg) and 3 ml normal saline i.m. at recovery room (Group A)
Study: 316976
Drug: Prophylactic propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic propranolol treatment postoperatively
Study: 316976
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of intravenous propranolol therapy
Study: 29016626
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitor (PPI)
Study: 29016626
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of PPI
Study: 29016626
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of PPI
Study: 15521106
Drug: Penicillin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (800 mg/day)
Study: 15521106
Drug: Diethylcarbamazine (DEC;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC; 1 mg/kg.day)
Study: 15521106
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of penicillin and DEC (at the same doses)
Study: 15521106
Drug: Framycetin ointment
Normalized name: framycetin
DrugBank: Framycetin (DB00452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Framycetin ointment
Study: 15521106
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets and placebo ointment
Study: 9684133
Drug: Multivitamin infusion
Normalized name: multivitamin infusion, adult no.2 without vit K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin infusion (Omnibionta) including 10 mg of alpha‐tocopherol acetate, 2 mg of DL‐alpha‐tocopherol, and 1 g of ascorbate
Study: 9684133
Drug: Multivitamin infusion
Normalized name: multivitamin infusion, adult no.2 without vit K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin infusion (Omnibionta)
Study: 8390768
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antioxidant treatment)
Study: 3072356
Drug: Ketoprofen 300
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen 300 mg
Study: 3072356
Drug: Aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 650 mg plus Codeine 60 mg
Study: 30265306
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg progesterone vaginal pessaries bid
Study: 30265306
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg progesterone vaginal pessaries bid
Study: 30265306
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg progesterone vaginal gel od
Study: 30265306
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg progesterone vaginal pessaries bid
Study: 30265306
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg progesterone vaginal pessaries od
Study: 28699555
Drug: Control Clusters
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Clusters (CC)
Study: 16464703
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Group Therapy for Adolescents (CBGT‐A)
Study: 16464703
Drug: Social Effectiveness
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Effectiveness Therapy for Adolescents‐‐Spanish version (SET‐Asv)
Study: 16464703
Drug: Intervención en
Normalized name: Salazopyrin EN
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervención en Adolescentes con Fobia Social‐‐Treatment for Adolescents with Social Phobia (IAFS)
Study: 11704914
Drug: Gd-EOB-DTPA (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gd-EOB-DTPA (3, 6, 12.5, 25, and 50 micromol/kg b. w. as a bolus injection)
Study: 11704914
Drug: Gd-DTPA (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gd-DTPA (0.1 mmol/kg b. w. as a bolus injection)
Study: 29346040
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (observation) (per-protocol population)
Study: 20502739
Drug: Physiological solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological solution
Study: 16364549
Drug: Placebo (fake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (fake analgesic cream)
Study: 8680609
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance assessed using the frequently sampled intravenous glucose tolerance test with minimal model analysis
Study: 30604599
Drug: Metformin, Sitagliptin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, Sitagliptin, and Acarbose (Met+Sita+Acarb)
Study: 30604599
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and Sitagliptin (Met+Sita)
Study: 10068082
Drug: Progesterone receptor
Normalized name: Progesterone receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone receptor (PgR) status
Study: 7736480
Drug: Beta-adrenergic chronic
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic chronic therapy
Study: 3437508
Drug: Trapidil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trapidil (400 mg daily on days 1 to 8, 200 mg on day 9)
Study: 31014775
Drug: (−)-epicatechin 1
Normalized name: EPICATECHIN
DrugBank: Epicatechin (DB12039)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (−)-epicatechin 1 mg/kg BW
Study: 31014775
Drug: (−)-epicatechin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: (−)-epicatechin 0.5 mg/kg BW
Study: 31014775
Drug: (−)-epicatechin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: (−)-epicatechin 0.1 mg/kg BW
Study: 26422126
Drug: Intravenous propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propranolol (0.15 mg/kg)
Study: 9161744
Drug: Atracurium (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.05 mg.kg‐1)
Study: 8424378
Drug: PPA (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPA (75 mg osmotic release oral system (OROS)‐PPA/d)
Study: 3122275
Drug: Misoprostol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (400 mcg)
Study: 27742998
Drug: EP217609 (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP217609 (4, 8, 12 mg)
Study: 27742998
Drug: Avidin (30-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avidin (30-min intravenous infusion)
Study: 19687579
Drug: cilnidipine 5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilnidipine 5-10 mg/day
Study: 19687579
Drug: amlodipine 5-7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine 5-7.5 mg/day
Study: 17684620
Drug: L-arginine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (7 grams per day for seven days)
Study: 15110198
Drug: Bivalirudin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg/hour infusion during the procedure)
Study: 15110198
Drug: Heparin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (70 U/kg initial bolus)
Study: 3608733
Drug: Arbacet 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbacet 25 micrograms four times daily
Study: 27367766
Drug: Standardized rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized rehabilitation therapy (SRT)
Study: 25176376
Drug: 22.63 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.63 mg/kg emulsified isoflurane
Study: 25176376
Drug: 38.26 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38.26 mg/kg emulsified isoflurane
Study: 25176376
Drug: 49.73 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 49.73 mg/kg emulsified isoflurane
Study: 21636188
Drug: Active manuka
Normalized name: manuka oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active manuka honey 20 ml 4 times daily for 6 weeks
Study: 21636188
Drug: Placebo (golden
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (golden syrup) 20 ml 4 times daily for 6 weeks
Study: 21636188
Drug: Active manuka
Normalized name: manuka oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active manuka honey and Placebo (golden syrup)
Study: 21029641
Drug: Shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu injection (SF injection) administered by peripheral intravenous infusion at initially 0.2 ml/kg and then 0.8 ml (kg/h) until the end of operations
Study: 21029641
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (Group N) administered similarly
Study: 21029641
Drug: Shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu injection (SF injection)
Study: 18684185
Drug: Single-dose lubiprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose lubiprostone (24 microg)
Study: 10415055
Drug: anti-TNF-alpha therapy
Normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-TNF-alpha therapy
Study: 7594063
Drug: Propionyl-L-carnitine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine (n = 99)
Study: 7594063
Drug: Propionyl-L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine (2 g/day)
Study: 2255726
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g POT II in a high-protein soup vehicle (70 kcal)
Study: 28107852
Drug: Topical chamomile
Normalized name: Chamomile
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical chamomile oil
Study: 21116816
Drug: Acetaminophen 650
Normalized name: acetaminophen 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg every 6 hours for 3 days
Study: 21116816
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg single dose prior to ZOL infusion
Study: 15291677
Drug: Olanzapine-Fluoxetine Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine-Fluoxetine Combination (OFC)
Study: 15291677
Drug: Control (Fluoxetine)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (Fluoxetine)
Study: 30341143
Drug: Combined steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined steroid and mycophenolate mofetil (MMF)
Study: 30341143
Drug: Standard steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard steroid treatment
Study: 18797832
Drug: Early orthodontic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early orthodontic treatment (bonded palatal expansion appliance and U-bow activator)
Study: 12812627
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (without CRRT)
Study: 10450833
Drug: Enalapril (ENA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (ENA), 10 mg o.d.
Study: 10450833
Drug: Nitrendipine (NIT),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (NIT), 20 mg o.d.
Study: 29956318
Drug: Titration method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration method
Study: 25088637
Drug: HSM IOL
Normalized name: iodine iolopride (123I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSM IOL (heparin-surface-modified hydrophobic acrylic intraocular lens)
Study: 20370727
Drug: Yun-chang capsule
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yun-chang capsule 70 mg plus placebo 35 mg (group A)
Study: 20370727
Drug: Yun-chang capsule
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yun-chang capsule 105 mg (group B)
Study: 20370727
Drug: Placebo 105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 105 mg (group C)
Study: 17646514
Drug: Topical EMLA
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical EMLA cream 60 min before block plus 2 mL IV normal saline 5 min before procedure
Study: 17646514
Drug: Topical sham
Normalized name: soap TOPICAL SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sham cream plus 2 mL IV normal saline
Study: 17646514
Drug: Topical sham
Normalized name: soap TOPICAL SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sham cream plus 0.1 microg/kg of sufentanil in 2 mL solution IV
Study: 16114181
Drug: Vanillin treatment
Normalized name: Vanillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vanillin treatment
Study: 2066644
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose octreotide (200 micrograms)
Study: 2066644
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose octreotide (400 micrograms)
Study: 2066644
Drug: Octreotide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide infusion (both doses)
Study: 6646402
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of lorazepam (Ativan)
Study: 28962602
Drug: SDT‐WL (Self-Determination
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDT‐WL (Self-Determination Theory-based Weight Loss Treatment)
Study: 28962602
Drug: BWL (Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: BWL (Standard Behavioral Weight Loss Treatment)
Study: 12324552
Drug: Warfarin (INR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR 2.8 to 4.2)
Study: 12324552
Drug: Warfarin (INR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR 2.0 to 2.5) and Aspirin (75 mg daily)
Study: 12324552
Drug: Warfarin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (both dosages)
Study: 10589612
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) - IV infusion of 15 mg/kg over 30 min, followed by 10 mg x kg(‐1) x hr(‐1) for 12 hours
Study: 10589612
Drug: Normovolemic hemodilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normovolemic hemodilution (NVHD) - blood removed to target hematocrit of approximately 28%, maintained with lactated Ringer's solution
Study: 1862210
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg oral test dose of haloperidol (HPDL)
Study: 1862210
Drug: Empirically determined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirically determined doses of HPDL (2, 4, or 10 mg b.i.d.)
Study: 24756766
Drug: Methylphenidate (Ritalin),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (Ritalin), a catecholamine reuptake blocker, dosage and duration not specified
Study: 15915401
Drug: Etomidate (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.10 mg/kg)
Study: 15915401
Drug: Midazolam (0.035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.035 mg/kg)
Study: 12595862
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (25 g daily for 6 weeks)
Study: 3907987
Drug: pivmecillinam plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivmecillinam plus pivampicillin (200 mg pivmecillinam plus 250 mg pivampicillin)
Study: 3907987
Drug: co-trimoxazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-trimoxazole (800 mg sulphamethoxazole plus 160 mg trimethoprim)
Study: 30101646
Drug: Fist Assist®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fist Assist® device (intermittent pneumatic compression) worn 6 hours daily for 30 days.
Study: 26478225
Drug: TPTD 56.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPTD 56.5 μg
Study: 23032083
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 2700 mg/day from day after surgery until day 30
Study: 22777865
Drug: ODN 50
Normalized name: ODN M362
DrugBank: ODN M362 (DB16485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODN 50 mg
Study: 22777865
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after switching from ODN 50 mg)
Study: 22777865
Drug: Continuous ODN
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ODN (10-50 mg)
Study: 22777865
Drug: Switched from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switched from ODN (10-50 mg) to placebo after 2 years
Study: 22777865
Drug: ODN (10-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODN (10-50 mg) for 5 years
Study: 22777865
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of ODN
Study: 19709169
Drug: Chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment for cancer
Study: 19709169
Drug: Subset of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subset of chemotherapy-treated adults
Study: 20350302
Drug: LY450139 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY450139 (100 mg)
Study: 20350302
Drug: LY450139 (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY450139 (140 mg)
Study: 15923270
Drug: Conventional 'fascial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 'fascial click' method using levobupivacaine 0.25% (0.3 ml kg(‐1))
Study: 10553847
Drug: Intrathecal 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 2.5 microg sufentanil, 1.25 mg bupivacaine, 25 microg epinephrine
Study: 10553847
Drug: Intrathecal 5
Normalized name: ZICONOTIDE 100MCG/ML INJ INTRATHECAL 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 5 microg sufentanil, 1.25 mg bupivacaine, 25 microg epinephrine
Study: 10553847
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: 1.25 mg bupivacaine, 25 microg epinephrine
Study: 26192386
Drug: Behavior activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior activation therapy
Study: 26070195
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment (ST) for 12 weeks (n=22)
Study: 23515409
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + Zoledronic Acid (ZOL)
Study: 19802403
Drug: Intravenous (iv)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (iv) outpatient treatment with amikacin or ceftriaxona, followed by oral antimicrobial after urine culture results, duration of iv treatment 2.9 days (SD 1.9)
Study: 19802403
Drug: Intravenous (iv)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (iv) inpatient treatment with amikacin or ceftriaxona, followed by oral antimicrobial after urine culture results, duration of iv treatment 2.8 days (SD 1.2)
Study: 17113895
Drug: Increased fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased fluid intake (1.5 L of extra water daily)
Study: 17113895
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one tablespoon of placebo syrup daily)
Study: 8087329
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 200 micrograms twice per day for 2 weeks
Study: 8087329
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 200 micrograms twice per day for 2 weeks
Study: 2676000
Drug: (2"R)-4'-O-tetrahydropyranyladriamycin (THP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (2"R)-4'-O-tetrahydropyranyladriamycin (THP) in combination with 5-fluorouracil (5-FU) and cyclophosphamide (CPA)
Study: 2676000
Drug: Adriamycin (ADR)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin (ADR) in combination with 5-fluorouracil (5-FU) and cyclophosphamide (CPA)
Study: 12932592
Drug: AF Suppression
Normalized name: Canesten AF
Approvals — FDA: no, EMA: no, PMDA: no
Description: AF Suppression Algorithm (treatment group)
Study: 11231208
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A and typhoid fever vaccine (25 microg typhoid Vi polysaccharide and at least 1,440 ELISA units of inactivated hepatitis A in a 1 mL dose)
Study: 11231208
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A and typhoid fever vaccine
Study: 2221314
Drug: High-dose fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fentanyl (0.05 mg/kg) and pancuronium (0.1 mg/kg)
Study: 2221314
Drug: Balanced anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced anesthesia with 0.02 mg/kg flunitrazepam, N2O/O2 1:1, isoflurane 0.5 vol%, and pancuronium (0.1 mg/kg) with a bolus of 0.005 mg/kg fentanyl
Study: 31759771
Drug: Simo decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simo decoction 20 ml q8h for 24 h